X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3460) 3460
Publication (341) 341
Book Review (23) 23
Book Chapter (10) 10
Dissertation (3) 3
Book / eBook (1) 1
Conference Proceeding (1) 1
Data Set (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2554) 2554
oncology (1950) 1950
index medicus (1821) 1821
male (1650) 1650
female (1628) 1628
middle aged (1502) 1502
chemotherapy (1427) 1427
aged (1368) 1368
rituximab (1362) 1362
chop (1284) 1284
antineoplastic combined chemotherapy protocols - therapeutic use (1268) 1268
hematology (1259) 1259
adult (1217) 1217
non-hodgkins-lymphoma (1135) 1135
treatment outcome (871) 871
prognosis (866) 866
cancer (834) 834
lymphomas (802) 802
elderly-patients (785) 785
lymphoma, large b-cell, diffuse - drug therapy (759) 759
aged, 80 and over (711) 711
r-chop (659) 659
chop chemotherapy (646) 646
cyclophosphamide - administration & dosage (641) 641
b-cell lymphoma (628) 628
vincristine - administration & dosage (612) 612
doxorubicin - administration & dosage (601) 601
antineoplastic combined chemotherapy protocols - administration & dosage (557) 557
survival (536) 536
prednisone - administration & dosage (534) 534
diffuse large b-cell lymphoma (514) 514
retrospective studies (498) 498
disease-free survival (493) 493
lymphoma (489) 489
therapy (467) 467
adolescent (444) 444
care and treatment (441) 441
lymphoma, non-hodgkin - drug therapy (421) 421
young adult (416) 416
trial (402) 402
cyclophosphamide (400) 400
chemotherapy plus rituximab (398) 398
lymphoma, large b-cell, diffuse - pathology (398) 398
cyclophosphamide - therapeutic use (393) 393
antibodies, monoclonal, murine-derived (391) 391
vincristine - therapeutic use (390) 390
antineoplastic combined chemotherapy protocols - adverse effects (389) 389
lymphoma, large b-cell, diffuse - mortality (385) 385
doxorubicin - therapeutic use (379) 379
survival analysis (361) 361
neoplasm staging (351) 351
antineoplastic agents - therapeutic use (350) 350
prednisone - therapeutic use (343) 343
survival rate (305) 305
analysis (296) 296
hemic and lymphatic diseases (296) 296
doxorubicin (287) 287
antibodies, monoclonal, murine-derived - administration & dosage (284) 284
medicine & public health (282) 282
follicular lymphoma (281) 281
transplantation (280) 280
follow-up studies (279) 279
phase-ii (277) 277
non-hodgkin's lymphomas (269) 269
risk factors (267) 267
antibodies, monoclonal - therapeutic use (265) 265
non-hodgkin's lymphoma (263) 263
vincristine (253) 253
antibodies, monoclonal, murine-derived - therapeutic use (248) 248
combined modality therapy (245) 245
expression (239) 239
randomized controlled-trial (239) 239
research (237) 237
lymphoma, b-cell - drug therapy (230) 230
lymphoma, large b-cell, diffuse - diagnosis (229) 229
cyclophosphamide - adverse effects (224) 224
anti-cd20 monoclonal-antibody (217) 217
remission induction (217) 217
vincristine - adverse effects (215) 215
apoptosis (214) 214
animals (213) 213
doxorubicin - adverse effects (211) 211
antibodies, monoclonal - administration & dosage (207) 207
dlbcl (205) 205
radiotherapy (199) 199
kaplan-meier estimate (192) 192
prednisone (192) 192
health aspects (190) 190
lymphoma, large b-cell, diffuse - therapy (188) 188
medicine, general & internal (188) 188
immune system diseases (187) 187
prednisone - adverse effects (184) 184
classification (178) 178
standard regimen chop (173) 173
patients (172) 172
plus rituximab (172) 172
3-weekly chop chemotherapy (171) 171
disease (170) 170
immunohistochemistry (170) 170
anthracyclines (167) 167
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3338) 3338
French (34) 34
German (25) 25
Japanese (21) 21
Spanish (19) 19
Russian (15) 15
Korean (9) 9
Chinese (3) 3
Polish (3) 3
Portuguese (2) 2
Serbian (2) 2
Hungarian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 07/2012, Volume 118, Issue 13, pp. 3377 - 3386
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 12, pp. 1250 - 1259
Journal Article
The Lancet Oncology, ISSN 1470-2045, 08/2017, Volume 18, Issue 8, pp. 1076 - 1088
The prognosis of young patients with diffuse large B-cell lymphoma at high risk (age-adjusted International Prognostic Index [aa-IPI] score 2 or 3) treated... 
CLINICAL-PRACTICE GUIDELINES | SURVIVAL | SUPPORT | IMPACT | CONSOLIDATION | RESPONSE CRITERIA | ONCOLOGY | R-CHOP | NON-HODGKIN-LYMPHOMA | ELDERLY-PATIENTS | MEGACHOEP | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Consolidation Chemotherapy | Cyclophosphamide - adverse effects | Lymphoma, Large B-Cell, Diffuse - therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Survival Rate | Cytarabine - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Intention to Treat Analysis | Vincristine - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Carmustine - administration & dosage | Stem Cell Transplantation - adverse effects | Stem cells
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 10/2012, Volume 118, Issue 19, pp. 4706 - 4714
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 4/2011, Volume 67, Issue 4, pp. 741 - 749
CMC-544 (inotuzumab ozogamicin) is a CD22-specific immunoconjugate of calicheamicin currently being evaluated in patients with non-Hodgkin’s B-cell lymphoma... 
Medicine & Public Health | Oncology | Cancer Research | CHOP | Immunoconjugate | Pharmacology/Toxicology | CVP | CMC-544 | CD22 | B-cell lymphoma | GEMTUZUMAB OZOGAMICIN | ACUTE MYELOID-LEUKEMIA | CD22-TARGETED IMMUNOCONJUGATE | DISEASE-FREE | PREDNISONE | ONCOLOGY | NON-HODGKINS-LYMPHOMA | MALIGNANCIES | CONJUGATE | PHARMACOLOGY & PHARMACY | ELDERLY-PATIENTS | Recurrence | Vincristine - pharmacology | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Male | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Drug Delivery Systems | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized | Time Factors | Vincristine - administration & dosage | Female | Doxorubicin - administration & dosage | Lymphoma, B-Cell - drug therapy | Prednisone - administration & dosage | Drug Administration Schedule | Antibodies, Monoclonal - pharmacology | Treatment Outcome | Mice, SCID | Survival | Xenograft Model Antitumor Assays | Animals | Antibodies, Monoclonal - administration & dosage | Mice, Nude | Cyclophosphamide - pharmacology | Lymphoma, B-Cell - pathology | Prednisone - pharmacology | Mice | Doxorubicin - pharmacology | Anthracyclines | Chemotherapy | Cyclophosphamide | Dexamethasone | Professional hockey | Lymphomas | Prednisone | Drug therapy, Combination | Comparative analysis | Cancer
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 2014, Volume 22, Issue 7, pp. 1833 - 1841
The objective of this study was to describe the incidence of grade 3/4 neutropenia, patterns of chemotherapy treatment, and granulocyte colony-stimulating... 
CHOP chemotherapy | Granulocyte colony-stimulating factor | Non-Hodgkin's lymphoma | Neutropenia | COLONY-STIMULATING FACTOR | SINGLE-ADMINISTRATION PEGFILGRASTIM | PHASE-III | RISK | LARGE-CELL LYMPHOMA | BREAST-CANCER | CANCER-PATIENTS | ONCOLOGY | FEBRILE NEUTROPENIA | HEALTH CARE SCIENCES & SERVICES | REHABILITATION | ELDERLY-PATIENTS | DAILY FILGRASTIM | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Age Factors | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Dose-Response Relationship, Drug | Young Adult | Lymphoma, Non-Hodgkin - blood | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Retrospective Studies | Neutropenia - chemically induced | Doxorubicin - administration & dosage | Lymphoma, Non-Hodgkin - drug therapy | Prednisone - administration & dosage | Prednisone - adverse effects | Risk Factors | Rituximab | Neutropenia - drug therapy | Neutropenia - prevention & control | Vincristine - adverse effects | Aged | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Granulocyte Colony-Stimulating Factor - administration & dosage | Chemotherapy | Cyclophosphamide | Anthracyclines | Corticosteroids | Prednisone | Macrophage colony stimulating factor | Non-Hodgkin's lymphomas | Cancer | Lymphomas | Preventive medicine | Toxicity
Journal Article